Analyses of factors involved in bone remodeling and inflammation in Ankylosing Spondylitis (AS) patients undergoing etanercept therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004838

Enrollment

Registered

2013-03-20

Start date

2008-03-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M45.00

Interventions

Group 1: Patients with ankylosing spondylitis, weekly etanercept (Enbrel) 50mg s.c. over 12 weeks. Prior to the start of therapy and after 4 and 12 weeks of treatment blood samples will be taken. The

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: AS patients meeting the criteria of the European Spondyloathropathy Study Group and eligible for treatment with Etanercept and healthy control individuals

Exclusion criteria

Exclusion criteria: Not meeting the inclusion criteria healthy control individuals demonstrating obvious signs of inflammation

Design outcomes

Primary

Measure	Time frame
Determination of erythrocyte sedimentation rate (ESR, lab results) prior to the start of therapy and after 4 and 12 weeks of treatment. Calculation of disease activity (BASDAI) through the evaluation of questionnaires filled out prior to the start of therapy and after 12 weeks of treatment.	—

Countries

Germany

Contacts

Public ContactGunther Neeck

Rheumazentrum Prof. Dr. med. G. Neeck

gunther.neeck@profneeck-rheumazentrum.de038203731920

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026